Vytrus Biotech S.A. risk profile
10 Contained slack in every measured input
Measured 1 September 2026 from VYT's filed statements. Recomputed nightly.
10 (Contained), driven by Market expectation at 61, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 61 | Stretched | Volatile | One-year price volatility — 68.0% |
| Operating pressure | 0 | Contained | Stable | Costs outgrowing revenue — -40.3 percentage points |
| Cash conversion | 35 | Normal | Worsening | Capital spending against operating cash — 0.69x |
| Leverage and coverage | 6 | Contained | Stable | Current ratio — 3.03x |
| Competitive position | 0 | Contained | Stable | Operating-margin gap against peers — +98.5 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for Vytrus Biotech S.A.